The purpose of this study is to evaluate the prevalence of clinically useful mutations in solid tumors. It focuses on patients with advanced or locally advanced solid tumors who are undergoing therapy.
This study investigates how liquid biopsy, a method for analyzing blood samples to detect tumor DNA, can identify mutations that may guide treatment decisions. It evaluates the use of these mutations as biomarkers to optimize therapy access.
- Who can participate: Adults 18 years or older with advanced or locally advanced solid tumors who can provide informed consent may participate.
- Study details: Participants will undergo liquid biopsy analysis to identify mutations. The study uses an investigational method to assess potential treatment biomarkers.
How understandable was the trial content above?
Hard to understand
Easy to understand